Synthetic peptides representing immunodominant epitopes of HIV 1 and HIV 2 together with a monoclonal antibody to p24 HIV-1 antigen are coated onto wells of a microplate. The peptides and the antibody have been carefully selected to ensure the screening of antibody and p24 antigen to all HIV-1 subtypes, including subtype O and HIV-2. Serum or plasma samples are added to these wells and, if antibodies specific to HIV-1 and/or HIV-2 (IgG, IgM or IgA) are present in the sample, they will form stable complexes with the HIV peptide antigens in the well. In case HIV-1 p24 is present in the sample, the antigen will be captured by the specific monoclonal antibody. Antigen-antibody complexes are then identified through the successive addition of: (1) biotinylated peptides, a biotinylated monoclonal antibody to HIV-1 p24, and; (2) horseradish peroxidase HRP Streptavidin conjugate. The hydrolytic activity of horseradish peroxidase allows for the quantification of these antibody-antigen complexes. Peroxidase substrate solution is then added. During incubation, a blue color will develop in proportion to the amount of anti-HIV-1/2 antibodies or HIV-1 p24 antigen bound to the well, thus establishing their presence or absence in the sample. Wells containing samples negative for anti-HIV antibody and/or p24 antigen remain colorless. A stop solution is added to each well and the resulting yellow color is read on a microplate reader at 450 nm..
Catalog # | KAPDHIV480 |
Format | ELISA |
Label | HRP |
Size | 480 Tests |
Sample Type | Serum, Plasma |
Sample Volume | 150 µL |
Controls | 4 levels |
Incubation | 60 min. 37°C/30 min. 37°C/30 min. 37°C/30 min. RT |
Shelf Life (weeks) | 60 |
Comments | Available on specific request |
Due to local registration requirement, this product can not be sold in Canada, Australia – without prior registration.
For Japan and Brazil, specific registration requirements are necessary. For more information, please contact: regulatory.affairs@diasource.be.